CAMBRIDGE, Mass., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences:
- Wedbush PacGrow Healthcare Conference, New York City
Date: August 16, 2016
Time: 9:45 a.m. ET
Presenter: Jeff Goater, chief financial officer
- 2016 Wells Fargo Securities Healthcare Conference, Boston
Date: September 7, 2016
Time: 8:45 a.m. ET
Presenter: Steven Paul, MD, president and chief executive officer
Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
The Company’s management team will also attend the following upcoming investor conferences for one-on-one meetings:
- Citi Annual Biotech Conference, Boston
Date: September 8, 2016
- Morgan Stanley Global Healthcare Conference, New York City
Date: September 14, 2016
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Investor Relations:
Matt Osborne
Head of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Katie EnglemanPure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com
Voyager Therapeutics
